Abbott splits into two units: Diversified Medical Products and Research-Based Pharmaceuticals

In a surprising release from Abbott Park (IL, USA) on October 19th (Wednesday) it was announced that Abbott will split up into two publically traded companies. While one unit will take care of its diversified medical products the other unit will be responsible for Abbott’s diversified medical products.

According to Miles D. White, the chairman and CEO of Abbott, this news is a significant event for Abbott and will reflect another dynamic change in Abbott’s 123 years history. This will ensure strengthened outlook and sustainable growth and shareholder returns, he said.

Abbott splits into two units: Portfolios of two companies


Research-based pharma company

Diversified medical products company

New name

To be named






Immunology, Multiple Sclerosis, Chronic kidney disease, Hepatitis C, Women’s health and oncology,    biologics and more


Medical products



Growth drivers


The company’s sustainable portfolio & advancing pipeline, including established biologics expertise


The company will generate nearly40 % of its sales in high-growth emerging markets, with further expansion expected in the coming years


Annual Sales
(2011 est.)

Nearly $18 Billion



Nearly $22 Billion






Humira, Lupron, Synagis, Zemplar, Kaletra, Creon, Duodopa, Synthroid, Androgel and others



Generics outside US, adult and pediatric nutritionals, core laboratory diagnostics, point of care and molecular diagnostics, and medical devices, including vascular devices, diabetes care, vision care and others

Source: [Abbott press release]

Recommended Posts